About BioAtla
BioAtla is a company based in San Diego (United States) founded in 2007. It operates as a HealthTech. BioAtla has raised $162.31 million across 5 funding rounds from investors including HHS, Janus Henderson Investors and Farallon Capital Management. The company has 76 employees as of December 31, 2024. BioAtla offers products and services including Conditionally Active Biologics (CAB). BioAtla operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
- Headquarter San Diego, United States
- Employees 76 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Bioatla, Inc.
-
Annual Revenue
$11 M (USD)0as on Dec 31, 2024
-
Net Profit
-$69.78 M (USD)43.48as on Dec 31, 2024
-
EBITDA
-$73.02 M (USD)43.16as on Dec 31, 2024
-
Total Equity Funding
$162.31 M (USD)
in 5 rounds
-
Latest Funding Round
$72.5 M (USD), Series D
Jul 15, 2020
-
Investors
HHS
& 7 more
-
Employee Count
76
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of BioAtla
BioAtla is a publicly listed company on the NASDAQ with ticker symbol BCAB in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of BioAtla
BioAtla offers a comprehensive portfolio of products and services, including Conditionally Active Biologics (CAB).
Therapeutics are developed for targeted cancer treatment activation.
People of BioAtla
Unlock access to complete
Unlock access to complete
Funding Insights of BioAtla
BioAtla has successfully raised a total of $162.31M across 5 strategic funding rounds. The most recent funding activity was a Series D round of $72.5 million completed in July 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in BioAtla
BioAtla has secured backing from 8 investors, including institutional and venture fund investors. Prominent investors backing the company include HHS, Janus Henderson Investors and Farallon Capital Management.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Venture capital is focused on healthcare by Pfizer's investment arm.
|
Locked | Locked | Locked | |
|
Multiple investment strategies are pursued by this hedge fund.
|
Locked | Locked | Locked |
Investor details for BioAtla
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by BioAtla
Investment portfolio details for BioAtla
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - BioAtla
Detailed financials for BioAtla
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Bioatla Comparisons
Peer comparison for BioAtla
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of BioAtla
BioAtla operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| Locked | Locked | Locked |
Small molecules are developed for cancer and skin disease treatments.
|
|
| Locked | Locked | Locked |
Cancer therapies are developed using selective pathway inhibitors.
|
Detailed competitors of BioAtla
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Bioatla
Complete news archive for BioAtla
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about BioAtla
BioAtla was founded in 2007 and raised its 1st funding round 7 years after it was founded.
BioAtla is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
BioAtla is a funded company, having raised a total of $162.31M across 5 funding rounds to date.
As of Dec 31, 2024, the latest employee count at BioAtla is 76.
Annual revenue of BioAtla is $11M as on Dec 31, 2024.
BioAtla, a San Diego-based biopharmaceutical company, is focused on developing safer and more effective drugs for cancer treatment. Its proprietary Conditionally Active Biologics (CAB) platform is utilized to create antibodies that activate under specific physiological conditions, targeting the unique microenvironment of diseased tissue. Solutions are provided for improved therapeutic outcomes in the oncology sector.
BioAtla's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
BioAtla offers Conditionally Active Biologics (CAB).
Yes, BioAtla is publicly traded on NASDAQ under the ticker symbol BCAB.
BioAtla has 8 investors. Key investors include HHS, Janus Henderson Investors, Farallon Capital Management, HBM Healthcare Investments, and Soleus Capital.
The ticker symbol of BioAtla is BCAB on NASDAQ.